As recently as 1990 it was stated that the use of oesophageal manometry in America was governed more by financial reimbursement than by clinical usefulness.' It has also been suggested that manometry is only worthwhile in the investigation of patients with non-cardiac chest pain.2 There are few reports of the cost effectiveness of manometry, but in one study published 10 years ago, Meshkinpour et al concluded that the cost of each change in patient management was $6482.00. 3 Our oesophageal laboratory serves a population of 1* 5 million people and is sited in a hospital which contains the regional thoracic surgery unit and the regional medical cardiology centre. New computerised equipment for performing oeso whom achalasia had been suspected on the basis of barium studies but in whom manometry was normal (see Table II At a cost of £63.00 per study the overall cost per change in management was £129.00.
Discussion
Despite the increasingly widespread use of oesophageal manometry, few studies have assessed its benefit to patient management. In a cost-benefit analysis in 1982, Meshkinpour et al calculated the cost per change in management to be $6482.00.3 Despite this high figure they concluded that oesophageal manometry was beneficial in patients with chest pain, dysphagia, and those in whom achalasia is suspected. The purpose of this study was to determine the costeffectiveness of oesophageal manometry in our laboratory.
The patterns of referral to our laboratory were similar to those experienced elsewhere,' except for a significant number of rheumatology patients, with 11 2% of all patients referred for assessment of suspected connective tissue disease.
In keeping with other studies of this nature, a manometric abnormality was significantly more common when dysphagia was the reason for referral.'9 Our finding that only one in 10 asymptomatic patients with known connective tissue disease had a manometric abnormality is at variance with previous studies in patients with scleroderma and mixed connective tissue disease.""'2 This may indicate early referral by our rheumatology department in keeping with the high percentage of these patients in our study.
The finding of a manometric abnormality in 30-6% of patients with non-cardiac chest pain is in keeping with other studies, which have shown an 18-58% prevalence.13 14 Long term follow up of these patients has shown that although they have similar mortality to an age matched control group, they have increased morbidity.'5 It has also been observed that although these patients continue to experience chest pain, the knowledge that the oesophagus is the source of this reduces their perception of the disability and their requests to see a physician. ' being the make-up of the patient populations. In Meshkinpour's study all patients had manometry performed routinely in addition to an oesophagogram, whereas in our study most patients were referred for manometry only when prior investigations had failed to identify the cause of their symptoms. Patient selection, therefore, affected their rate of positive diagnosis, which was only 14% compared with 50 7% in our study. Secondly, Meshkinpour did not regard confirmation of a diagnosis as influencing patient management whereas we felt that it was of value in certain situations such as in patients with suspected achalasia before myotomy. Thirdly, in the study by Meshkinpour over a third of the patients were referred with gastrooesophageal reflux disease compared with 14-2% in our study, and it was this patient population which yielded the smallest number of positive diagnoses in our experience. Finally, Meshkinpour's figures were calculated on the basis of hospital charges for manometry, whereas our figure was derived from actual costs. Even a decade ago their charge was significantly higher than our calculated cost.
In conclusion, oesophageal manometry changed management in over 20% of patients with gastro-oesophageal reflux disease and noncardiac chest pain and in over 60% of patients with dysphagia. The overall cost per alteration in management was £129.00. It is, therefore, a useful and cost effective test in the management of patients with these symptoms.
